• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro susceptibilities of common pediatric pathogens to LY163892.常见儿科病原体对LY163892的体外敏感性
Antimicrob Agents Chemother. 1988 Feb;32(2):268-70. doi: 10.1128/AAC.32.2.268.
2
Comparative in-vitro activity of a new oral carbacephem, LY163892.
J Antimicrob Chemother. 1988 Oct;22(4):445-56. doi: 10.1093/jac/22.4.445.
3
In vitro activity of BAY v 3522, a new oral cephalosporin.新型口服头孢菌素BAY v 3522的体外活性
Antimicrob Agents Chemother. 1990 Sep;34(9):1855-7. doi: 10.1128/AAC.34.9.1855.
4
In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.新型口服碳头孢烯类抗菌剂氯碳头孢（LY163892）对流感嗜血杆菌和卡他莫拉菌呼吸道分离株的体外活性
Antimicrob Agents Chemother. 1991 Jul;35(7):1504-7. doi: 10.1128/AAC.35.7.1504.
5
In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.头孢地尼对西西里岛分离出的呼吸道病原体的体外活性及β-内酰胺酶产生情况
J Chemother. 1996 Jun;8(3):193-9. doi: 10.1179/joc.1996.8.3.193.
6
In-vitro activity and beta-lactamase stability of LY163892.
J Antimicrob Chemother. 1988 Aug;22(2):155-65. doi: 10.1093/jac/22.2.155.
7
Global surveillance of bacterial susceptibility to cefaclor: 1988-1990.1988 - 1990年全球头孢克洛细菌敏感性监测
Clin Ther. 1993 Jan-Feb;15(1):88-96.
8
[Serotype distribution and drug resistance of , and isolated from nasopharynx of Uygur children].[从维吾尔族儿童鼻咽部分离出的、和的血清型分布及耐药性]
Zhonghua Er Ke Za Zhi. 2018 Apr 2;56(4):279-283. doi: 10.3760/cma.j.issn.0578-1310.2018.04.008.
9
In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.中国社区获得性呼吸道感染患者肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的体外药物敏感性研究：头孢地尼及其他比较药物的活性
Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. Epub 2012 Apr 21.
10
Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.头孢克肟在卡他莫拉菌（布兰汉菌）存在的情况下对肺炎链球菌、化脓性链球菌和流感嗜血杆菌的抗菌活性。
Chemotherapy. 1992;38(1):28-35. doi: 10.1159/000238939.

引用本文的文献

1
The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.β-内酰胺类抗生素之间的化学关系及其对反应活性和分解的潜在影响。
Front Microbiol. 2022 Mar 24;13:807955. doi: 10.3389/fmicb.2022.807955. eCollection 2022.
2
Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.氯碳头孢。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1993 May;45(5):716-36. doi: 10.2165/00003495-199345050-00008.
3
Pharmacokinetics of LY163892 in infants and children.LY163892在婴幼儿和儿童中的药代动力学。
Antimicrob Agents Chemother. 1988 Nov;32(11):1738-9. doi: 10.1128/AAC.32.11.1738.
4
Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.储存及药敏试验条件对LY163892及其他四种头孢菌素稳定性和活性的影响
Antimicrob Agents Chemother. 1988 Oct;32(10):1477-80. doi: 10.1128/AAC.32.10.1477.
5
Loracarbef concentrations in middle ear fluid.氯碳头孢在中耳液中的浓度。
Antimicrob Agents Chemother. 1990 Oct;34(10):2030-1. doi: 10.1128/AAC.34.10.2030.
6
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.氯碳头孢与阿莫西林-克拉维酸治疗急性中耳炎的比较评价
Antimicrob Agents Chemother. 1991 May;35(5):967-71. doi: 10.1128/AAC.35.5.967.
7
Pharmacokinetics of loracarbef in pediatric patients.
Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):201-4. doi: 10.1007/BF03190146.
8
Pharmacokinetics of loracarbef and interaction with acetylcysteine.
Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):851-5. doi: 10.1007/BF01960891.
9
Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.
Infection. 1992 May-Jun;20(3):176-82. doi: 10.1007/BF01704619.
10
Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.氯碳头孢与青霉素V治疗链球菌性咽炎和扁桃体炎的比较。
Infection. 1992 Sep-Oct;20(5):301-8. doi: 10.1007/BF01710806.

常见儿科病原体对LY163892的体外敏感性

In vitro susceptibilities of common pediatric pathogens to LY163892.

作者信息

Shelton S, Nelson J D

机构信息

Department of Pediatrics, University of Texas Health Science Center, Dallas 75235.

出版信息

Antimicrob Agents Chemother. 1988 Feb;32(2):268-70. doi: 10.1128/AAC.32.2.268.

DOI:10.1128/AAC.32.2.268
PMID:3129989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172150/
Abstract

LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and amoxicillin-clavulanic acid. It has greater stability than cefaclor and greater activity against beta-lactamase-producing Haemophilus influenzae and Escherichia coli. LY163892 is less active than amoxicillin against streptococci and less active than amoxicillin-clavulanic acid against Branhamella catarrhalis but comparable against other pathogens.

摘要

LY163892是一种口服碳头孢烯类抗生素，其抗菌谱与头孢克洛和阿莫西林-克拉维酸相似。它比头孢克洛具有更高的稳定性，对产β-内酰胺酶的流感嗜血杆菌和大肠杆菌具有更强的活性。LY163892对链球菌的活性低于阿莫西林，对卡他莫拉菌的活性低于阿莫西林-克拉维酸，但对其他病原体的活性相当。